Introduction {#Sec1}
============

In December 2019, an outbreak of a coronavirus disease 2019 (COVID-19) occurred in Wuhan, China, and the disease subsequently spread to approximately 200 countries within approximately 3 months. On March 11, 2020, the World Health Organization (WHO) declared the outbreak a pandemic \[[@CR1]--[@CR3]\]. Approximately 2--5% of COVID-19 cases result in death from massive alveolar damage and progressive respiratory failure \[[@CR4], [@CR5]\]. Although the death rate is lower than that of the coronaviruses causing severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome, the highly contagious nature of the 2019 novel coronavirus (SARS-CoV-2) has been a factor in an increasing number of deaths from COVID-19 in almost all countries \[[@CR6]\]. Efforts to prevent the spread of infection and reduce mortality are actively underway in each affected country. Knowledge of the risk factors for COVID-19 patient mortality is essential because it will help government leaders develop more efficient strategies for confronting the COVID-19 outbreak, and help clinicians prioritize care for patients with higher mortality risk. Although a few previous studies have investigated risk factors for mortality, most are limited because they do not consider a range of potential factors \[[@CR7]--[@CR9]\]. Furthermore, due to the limited number of previous studies, risk factors for mortality have not been definitively examined.

After the outbreak in China, the number of COVID-19 cases in South Korea immediately increased due to South Korea's close geographic location to China and the number of people who travel between the two countries. In the current study, we evaluated risk factors for death in COVID-19 patients by considering several possible factors using data from two hospitals in Daegu, South Korea. Furthermore, we studied whether underlying neurological diseases are risk factors for death.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

This retrospective cohort study included two cohorts of adult inpatients (≥ 18 years old) from Kyungpook National University Hospital and Kyungpook National University Chilgok Hospital in Daegu, South Korea. In our study, all adult patients who were diagnosed with COVID-19 according to the WHO interim guidance were screened. Those who were discharged or died between February 1, 2020 (i.e., when the first patients were admitted), and March 25, 2020, were included in the study.

These two hospitals are the largest among the four designated explicitly for patients in the COVID-19 severe stage transferred from other hospitals in Daegu. Therefore, our study enrolled adult inpatients that were hospitalized for the near severe stage of COVID-19 and had an outcome of either discharged or dead in the early stages of the outbreak. As of March 26, 2020, 27.7% of COVID-19 deaths in Daegu and 20.0% of COVID-19 deaths in South Korea were included in this study. This study was approved by the Institutional Review Board of Kyungpook National University Hospital, and the requirement for informed consent was waived by the Ethics Commission as described previously.

Data collection {#Sec4}
---------------

Clinical, demographic, epidemiological, treatment, medication, and outcome data were extracted from electronic medical records. All data were independently investigated by two physicians (JH and JK) using standardized data collection forms. Discrepancies were resolved through discussion with a third investigator (DP), and by referring to the original articles. Neurological diseases such as stroke, Parkinson's disease, and Alzheimer's dementia (AD) were reconfirmed by a neurologist (JP).

Laboratory procedures {#Sec5}
---------------------

Before January 31, 2020, pancoronavirus RT-PCR was used to identify coronavirus in Korea. This test requires two separate assays over a 24-h testing period \[[@CR10]\]. After January 31, 2020, each local government's Public Health and Environmental Research Institute began diagnosing COVID-19 using the RT-PCR kit approved by the Korean Centers for Disease Control and Prevention (KCDC) and the Korean Ministry of Food and Drug Safety \[[@CR11]\]. Since February 7, 2020, more than 50 private medical institutions in South Korea, which were approved by the KCDC, began to test for SARS-CoV-2 using the RT-PCR kit. Both nasopharyngeal and oropharyngeal swabs were used to diagnose COVID-19 \[[@CR11]\].

Risk factors {#Sec6}
------------

The patient's underlying chronic medical and neurological diseases were investigated based on national health insurance system of South Korea diagnosis codes. All underlying neurological diseases such as stroke, idiopathic Parkinson's disease (IPD), and AD were reconfirmed by a neurologist.

Based on previous studies of COVID-19 risk factors and the classification system announced by the KCDC, the presence of chronic medical underlying diseases such as diabetes, chronic kidney disease (CKD), chronic lung, or cardiovascular disease, carcinoma, dyslipidemia, and hypertension were investigated (Fig. [1](#Fig1){ref-type="fig"}). Chronic lung disease was defined as chronic obstructive pulmonary disease, asthma, interstitial lung disease, idiopathic pulmonary fibrosis, or bronchiectasis. Additionally, we investigated the presence of neurological disorders including stroke, IPD, and AD in COVID-19 patients. Patients with a medication history involving ARBs or ACE inhibitors and NSAIDs, such as ibuprofen, were also included in the study. It is important to note that NSAIDs have recently been suspected to be related to COVID-19 through the angiotensin-converting enzyme 2 (ACE2).Fig. 1Classification of patients with coronavirus disease 2019 (COVID-19) and protective methods according to classification. There are four classification stages in South Korea: asymptomatic, mild, moderate, and severe. The asymptomatic stage meets all of the following conditions: (1) fully conscious, (2) \< 50 years old, (3) no underlying disease, (4) non-smoker, and (5) \< 37.5 °C temperature without antipyretics. The mild stage is full consciousness with one or more of the following conditions: (1) ≥ 50 years old, (2) ≥ 1 underlying disease, and (3) ≤ 38 °C temperature after taking antipyretics. The moderate stage is full consciousness and one or more of the following conditions: (1) \> 38 °C temperature even after taking antipyretics and (2) respiratory difficulty. The severe stage is when the patient is unconscious. Underlying diseases: diabetes, chronic kidney disease, chronic liver disease, chronic lung disease, chronic cardiovascular disease, blood cancer, cancer patients undergoing chemotherapy, patients taking immunosuppressant drugs, and human immunodeficiency virus disease

Statistical analysis {#Sec7}
====================

To identify differences in demographic data between COVID-19 survivors and non-survivors, two sample *t* tests, Mann-Whitney *U* tests, or Chi-squared tests were performed, as appropriate. In addition, to analyze the correlation between the clinical parameters of underlying diseases and survival rates in COVID-19 patients, the Cox proportional hazards regression model was used, and the values of the beta coefficient, standard error, hazard ratio, confidence interval of hazard ratio, and *p* were used for multivariate analysis. To evaluate the predictive factor accuracy of age for mortality in patients with COVID-19, we performed a receiver operating characteristic (ROC) analysis. Survival analysis was performed using Kaplan--Meier method, and differences in patient survival periods were determined by employing the log-rank test with respect to the presence of AD. All statistical analyses were conducted using SPSS version 22.0 (IBM, Armonk, NY, USA).

Results {#Sec8}
=======

Patient demographics {#Sec9}
--------------------

A total of 103 adult patients who were hospitalized at Kyungpook National University Hospital and Kyungpook National University Chilgok Hospital for COVID-19 before March 26, 2020, were enrolled in the final analysis of this study. Twenty-six patients died during hospitalization, and 77 were discharged. Mean patient age was 67.62 ± 15.32 years, with ages ranging from 24 to 97 years, and the sex ratio (male:female) was 52:51 (Table [1](#Tab1){ref-type="table"}). Comorbidities were present in 72.6% of the patients. Hypertension was the most common comorbidity affecting 55.3% of patients, followed by diabetes (34.0%) and CKD (16.5%) (Table [1](#Tab1){ref-type="table"}).Table 1Clinical characteristics of patients with COVID-19VariableTotalSurvivorNon-survivor*p* valueTotal, *n* (%)103 (100%)77 (75%)26 (25%)Age, years67.62 ± 15.3264.62 ± 15.8476.50 ± 9.25.000\*Gender, *n* (%)  Female51 (50%)41 (53%)10 (38%).192  Male52 (50%)36 (47%)16 (62%)Comorbidities  Hypertension57 (55%)40 (52%)17 (65%).233  Diabetes mellitus35 (34%)21 (27%)14 (54%).013\*  Chronic kidney disease17 (17%)14 (18%)3 (12%).430  Dyslipidemia13 (13%)10 (13%)3 (12%).848  Chronic lung disease7 (7%)2 (3%)5 (19%).004\*  Carcinoma9 (9%)5 (6%)4 (15%).165  Cardiovascular disease12 (12%)6 (8%)6 (23%).036\*  Dementia11 (11%)3 (4%)8 (31%).000\*  Parkinson disease2 (2%)1 (1%)1 (4%).416  Stroke4 (4%)1 (1%)3 (12%).019\*  Taking NSAIDs5 (5%)3 (4%)2 (8%).436  Taking ARB or ACEi13 (13%)8 (10%)5 (19%).338Hospitalization type  Ward77 (75%)57 (74%)20 (77%).769  ICU26 (25%)20 (26%)6 (23%)Types of intensive care  Mechanical ventilator27 (26%)22 (29%)5 (19%).349  ECMO4 (4%)2 (3%)2 (8%).245*p* values were calculated by independent *T* test or Chi-square test as appropriate*ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *COVID-19* coronavirus disease 2019, *ARB* angiotensin receptor blocker, *ACEi* angiotensin-converting enzyme inhibitor, *NSAIDs* non-steroidal anti-inflammatory drugs\*Significant difference noted compared between two groups (*p* \< .05). Values: mean ± standard deviation

Treatment methods {#Sec10}
-----------------

Of the 103 patients, four (3.9%) were treated with extracorporeal membrane oxygenation (ECMO), 27 (26.2%) were intubated and placed on a mechanical ventilator, and 26 (25.2%) were treated in the intensive unit care (ICU). All hospitalized patients were treated with either two tablets of lopinavir/ritonavir 200 mg/50 mg (Kaletra®, AbbVie Inc., North Chicago, IL, USA) alone or a combination of two tablets of lopinavir/ritonavir 200 mg/50 mg and hydroxychloroquine sulfate 400 mg (Oxiklorine®, Myungmoon Pharm. Co., Ltd., Seoul, South Korea) for anti-viral treatment. With the exception of four surviving patients, all other patients received treatment with the listed oral medications.

Risk factors for non-survival {#Sec11}
-----------------------------

Comparing the demographic data between survivor and non-survivor COVID-19 patients, there was a significant difference in age (*p* \< 0.05) (Table [1](#Tab1){ref-type="table"}). In a comparison of underlying disease comorbidities between survivor and non-survivor COVID-19 patients, the presence of diabetes, chronic lung disease, coronary vascular disease, AD, and stroke was significantly higher in the non-survivor group compared with the survivor group (*p* \< 0.05) (Table [1](#Tab1){ref-type="table"}). However, the presence of hypertension, CKD, IPD, or dyslipidemia was not significantly different between the non-survivor and survivor groups. However, patients with a history of taking ARBs or ACE inhibitors, as well as NSAIDs, showed no statistically significant differences in death rate.

In a multivariate logistic analysis, age and the presence of chronic lung disease and AD were the only significant parameters for predicting COVID-19 non-survivors (*p* \< 0.05) (Table [2](#Tab2){ref-type="table"}). In COVID-19 patients, the area under the ROC curve on age for predicting non-survival was 0.742 (95% CI, 0.646--0.823; *p* \< 0.0001) (Table [3](#Tab3){ref-type="table"}). The optimal cutoff value obtained from the maximum Youden Index (J) was 70 (sensitivity, 80.77%; specificity, 61.04%), and the odds ratio of non-survival increased 1.055 fold for every year of age (Fig. [2](#Fig2){ref-type="fig"}).Table 2Risk factors associated with mortality in patients with COVID-19 using multivariate logistic analysisParameterBeta coefficientStandard errorHR (95% CI)*p* valueAge.053.0261.055 (1.003--1.109).039\*Diabetes mellitus1.090.5872.974 (0.942--9.390).063Chronic lung disease2.615.96113.665 (2.077--89.915).007\*Cardiovascular disease.939.7982.556 (0.535--12.207).239Alzheimer's dementia2.041.8367.698 (1.496--39.610).015\*Stroke− 1.2761.3250.279 (0.021--3.747).335*p* values by cox proportional hazard model*HR* hazard ratio, *CI* confidence interval\*Statistical significant with *p* \< .05Table 3ROC curve analysis of age for mortality of COVID-19ParameterAUCStandard error*p* value95% CIAge.742.052.000\*0.640--0.844*AUC* area under the ROC curve, *CI* confidence interval^\*^Significant difference noted (*p* \< .05)Fig. 2The area under the ROC curve for age predicting non-survival was 0.742 (95% CI, 0.640--0.844; *p* \< 0.0001). The optimal cutoff value obtained from the maximum Youden Index (J) was 70 (sensitivity, 80.8%; specificity, 61.0%), and the odds ratio for non-survival increased 1.055 fold for every year of age

AD as a risk factor for mortality {#Sec12}
---------------------------------

Of the 11 AD patients with COVID-19, eight (72.72%) died. The AD patients with COVID-19 who were included in this study are shown in Table [3](#Tab3){ref-type="table"}. The average age of AD patients with COVID-19 was 80.27 ± 10.10 years, with ages ranging from 58 to 97 years, and the sex ratio (male:female) was 6:5. The survival rate of 31% was lower among COVID-19 patients with AD compared to 5% for COVID-19 patients without AD. The difference in survival rates according to the presence of AD was statistically significant (*p* \< 0.0001) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Cumulative survival of patients with COVID-19 based on the presence of Alzheimer's dementia (AD). The difference in survival rates according to the presence of AD was statistically significant (*p* \< 0.0001)

Discussion {#Sec13}
==========

In the current study, we evaluated risk factors for mortality in patients with COVID-19 by analyzing the data from two major hospitals in Daegu, in which only patients with severe symptoms were admitted. Our study included approximately 20% of the total COVID-19 death cases in South Korea. Of the 103 included patients, 26 (25.2%) died despite active treatment with anti-viral medication, ECMO, and mechanical ventilation. We found that the presence of chronic lung disease and AD were predictive factors for death from COVID-19, especially mortality risk increases beginning at the age of 70 years.

Our findings showing that older age is one of the risk factors for mortality in patients with COVID-19 correspond with previous studies \[[@CR7], [@CR9]\]. The study by Zhou et al. \[[@CR9]\] included 191 patients. Of these patients, 54 died, and it was reported that increased age was associated with death in COVID-19 patients. In addition, Porcheddu et al. \[[@CR7]\] reported, in the early stages of the outbreak in northern Italy, that death mainly occurred in older patients. It was proposed that age-dependent functional defects in immunologic cells, such as T cells and B cells, and the excess production of various cytokines could result in impaired control of viral replication \[[@CR12], [@CR13]\]. Prolonged proinflammatory responses in older adults may also be responsible for the high death rate in patients in this age group \[[@CR14]\].

Regarding underlying diseases, we found that chronic lung disease and AD increase the mortality rate in COVID-19 patients. In previous studies, several diseases, including diabetes, hypertension, coronary artery disease, cerebrovascular diseases, chronic renal disease, and chronic lung disease, are reported to be risk factors for death from COVID-19 \[[@CR15]--[@CR17]\]. This discrepancy might be due to the relatively small sample size in our study. However, our finding that AD is risk factor of death from COVID-19 has not been previously reported. Alterations in the peripheral immune response are known to play a role in AD pathology \[[@CR18]--[@CR20]\]. Busse et al. \[[@CR21]\] reported that, compared to an age-matched healthy control group, 60 patients with AD had decreased numbers of B cells and T cells. The number of regulatory T cells (e.g., CD4+ and CD8+ T cells), which plays a critical role in maintaining peripheral tolerance and controlling acute, persistent infections, was notably altered in AD, but not in other types of dementia, such as vascular or frontotemporal dementia \[[@CR21]\]. Therefore, unlike stroke associated with vascular dementia, it is thought that the significant increase in mortality in AD patients with COVID-19 might be due to these alterations in the peripheral immune response.

SARS-CoV-2 binds to ACE2 in the human body \[[@CR22]\]. ACE2 is known to be expressed broadly in the lungs, heart, blood vessels, brain, and intestines \[[@CR23]\]. Of these target organs, the lungs are the most vulnerable to SARS-CoV-2 infection. There have been concerns that ACE inhibitors and ARBs might increase ACE2 expression and increase patients' susceptibility to SARS-CoV-2 \[[@CR24]\]. Furthermore, it has been proposed that NSAID use might weaken inflammatory effects that suppress SARS-CoV-2 survival \[[@CR25]\]. However, our study showed that the use of those medications is not associated with changes in COVID-19 death rates.

In our study, we found that older patients, especially those over the age of 70 years, are likely to die from COVID-19. In addition, the presence of chronic lung disease and AD predicted a higher risk of death. Therefore, we recommend close observation and active symptom treatment when patients with COVID-19 have the previously mentioned risk factors (old age, chronic lung disease, and AD). In addition, the government should pay special attention to, and continue developing new measures for, preventing SARS-CoV-2 infection in patients with risk factors for mortality. To the best of our knowledge, this is the first study to show that AD increases the death rate of COVID-19 patients. However, our study is limited in that it was conducted retrospectively using a small number of COVID-19 cases. Further studies are therefore necessary to address these limitations.
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